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Introduction
Neuroinflammation, an immune response to neuronal insult, is
a core component of many disorders such as stroke, multiple
sclerosis (MS), neurodegenerative disorders, and brain tu-
mours.[1] There is a major need to understand the role of neu-
roinflammation in these pathologies and thereby support the
development of therapeutics. One approach for assessing neu-
roinflammation in vivo is by the use of positron emission to-
mography (PET) imaging with radiopharmaceuticals that are
selective for the 18-kDa translocator protein (TSPO), a protein
with five transmembrane helical domains localised primarily in
the outer mitochondrial membrane.[2, 3] Neuroinflammation is
driven at least in part by the activation of microglia, the brain’s
resident macrophages, accompanied by a significant upregula-
tion of TSPO. Therefore, imaging TSPO expression is a powerful
approach for investigating neuroinflammation. The most com-
monly used TSPO PET radiotracer is R-1-(2-chlorophenyl)-N-
methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide ((R)-
[11C]PK11195, [11C]1, Figure 1), which is a selective antagonist of
TSPO that binds with nanomolar affinity (9.3 nm).[1, 4] (R)-[11C]1
has been used in PET imaging to show neuroinflammation
in vivo in cases of stroke, neurodegeneration, traumatic brain
injury, and neoplasia.[5] However, there are a number of chal-
lenges that hinder the wider use of [11C]1 in research and clini-
cal settings, such as low brain permeability,[1, 4, 6] high nonspe-
cific and variable plasma protein binding, and the short half-
life of carbon-11 (t1/2=20 min), which restricts its use to PET
centres that have a cyclotron on site.
Given these limitations of [11C]1, multiple new TSPO radio-
tracers have been developed and studied; these have im-
Translocator protein (TSPO) is a biomarker of neuroinflamma-
tion, which is a hallmark of many neurodegenerative diseases
and has been exploited as a positron emission tomography
(PET) target. Carbon-11-labelled PK11195 remains the most ap-
plied agent for imaging TSPO, despite its short-lived isotope
and low brain permeability. Second-generation radiotracers
show variance in affinity amongst subjects (low-, mixed-, and
high-affinity binders) caused by the genetic polymorphism
(rs6971) of the TSPO gene. To overcome these limitations, a
new structural scaffold was explored based on the TSPO phar-
macophore, and the analogue with a low-affinity binder/high-
affinity binder (LAB/HAB) ratio similar (1.2 vs. 1.3) to that of (R)-
[11C]PK11195 was investigated. The synthesis of the reference
compound was accomplished in six steps and 9% overall yield,
and the precursor was prepared in eight steps and 8% overall
yield. The chiral separation of the reference and precursor
compounds was performed using supercritical fluid chroma-
tography with >95% ee. The absolute configuration was de-
termined by circular dichroism. Optimisation of reaction condi-
tions for manual radiolabelling revealed acetonitrile as a pre-
ferred solvent at 100 8C. Automation of this radiolabelling
method provided R and S enantiomers in respective 21.3:
16.7 and 25.6:7.1% decay-corrected yields and molar activi-
ties of 55.8:35.6 and 63.5:39.5 GBqmmol@1 (n=3). Injection
of the racemic analogue into a healthy rat confirmed passage
through the blood–brain barrier.
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proved properties for application, including several that are la-
belled with the longer-lived radioisotope fluorine-18 (t1/2=
109.9 min).[1] However, PET studies using these second-genera-
tion radiotracers, such as N-(2-(methoxy-11C)benzyl)-N-(4-phe-
noxypyridin-3-yl)acetamide ([11C]PBR28, [11C]2, Figure 1), identi-
fied a variance in affinity to these compounds between sub-
jects. This affinity variation was determined to be caused by a
genetic polymorphism (rs6971) found in exon 4 of the TSPO
gene, which results in substitution of alanine for a threonine at
position 147 (A147T). Thus three distinct subject groups have
been identified: high-affinity binders (HABs; Ala/Ala), low-affini-
ty binders (LABs; Thr/Thr), and mixed-affinity binders (MABs;
(Ala/Thr).[1]
Although previous research has yielded many new radiotrac-
ers for imaging TSPO, to date only [11C]1 binds highly inde-
pendent of TSPO gene polymorphism (e.g. , it binds to both
LAB and HAB binding sites equally, as indicated by the LAB/
HAB ratio of 1, Table 2), thus prompting further research into
the development of an optimised TSPO PET radiotracer, which
will ideally have the improved pharmacokinetic properties of
second-generation TSPO radiotracers and be independent of
the observed polymorphism.
In 2004, a study by Okubo et al. described a tetracyclic
indole-based pharmacophore (4, Figure 2) with high affinity for
TSPO.[7] Based on this structural scaffold, a tricyclic derivative
[18F]GE180 ([18F]5, Figure 2) was developed with good affinity
for TSPO. From radiotracer retention, biodistribution, and
in vivo metabolic profile studies, [18F]5 showed high specific
binding, good brain uptake, high uptake and retention in the
olfactory bulb (TSPO-enriched region), and good clearance
from striatum (region of low TSPO expression) in rats.[8] This ra-
diotracer has now been evaluated in humans for imaging
TSPO expression.[9–12]
However, while [18F]5 demonstrated less dependence than
other second-generation tracers on the single nucleotide poly-
morphism, its affinity for TSPO still differs significantly amongst
the three binding groups (binding affinity ratio LABs/HABs=
5.1).[13] Therefore, there is still a need to develop a TSPO radio-
tracer with low sensitivity toward this polymorphism.
Toward this objective informed by structure–activity design
features, a novel series of compounds based on the chemical
scaffold[14] of 5 ((S)-GE180) were developed and synthesised. A
key design feature being that while retaining good affinity for
TSPO, variation at the amide position could influence the LAB/
HAB ratio. From this, the compound with most appropriate
properties for development as a potential TSPO PET radiotracer
with low binding sensitivity to the human gene polymorphism
rs6971 was identified as 6 (GE387), the enantiomers of which
were shown to have affinities of 1.04 nm (which, later in this
work we identified to be the S form, as outlined in the Results
and Discussion section below) and 22 nm (identified to be the
R form)[14] based on a rat heart TSPO assay.[15] Herein we report,
for compound 6, determination of relative binding affinities to
confirm low sensitivity to the genetic polymorphism, synthesis
of reference compound 6 and precursors for radiolabelling
with fluorine-18, separation and identification of enantiomers,
and finally the development of protocols for the automated ra-
diosynthesis of its radiolabelled analogue [18F]6 as well as the
initial in vivo preclinical PET.
Results and Discussion
Chemistry
For the radiolabelling of [18F]6, we proposed an SN2 nucleophil-
ic substitution of a good leaving group with [18F]fluoride, for
which reason tosylate 25 and mesylate 26 were envisioned as
potential precursors. Reference compound 6 (Scheme 1) and
the respective radiolabelling precursors 25 and 26 (Schemes 2
and 3) were prepared by following previously reported synthe-
ses of reference compound and mesylate precursors of 6.[16]
2-Fluoroethanol 7 was tosylated in pyridine to form 2-fluo-
roethyl tosylate 8. Tosylate 8 was used to alkylate 2-chloro-5-
methoxyaniline 9 to afford 10 (Scheme 1). The methoxyaniline
10 was then deprotonated with KHMDS in THF and reacted
with bromide intermediate 11 to give enol 12, which subse-
quently underwent cyclisation assisted with zinc chloride in di-
ethyl ether at reflux to afford the tricyclic product 13, isolated
in 31% yield over two steps. Chloro analogue 13 was dehalo-
genated with hydrogen on activated palladium to obtain ester
14, which was hydrolyzed to acid 15. The crude acid 15 was
Figure 1. First- and second-generation TSPO PET radiotracers.
Figure 2. Pharmacophore-derived second-generation analogues.
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reacted with N-ethylbenzylamine via an acid chloride inter-
mediate 16 formed with oxalyl chloride to form the reference
standard 6 with a yield of 28% over four steps.
Analogously, 2-chloro-5-methoxyaniline hydrochloride 9 re-
acted with benzyloxyacetaldehyde 17 under reductive condi-
tions to form the amine 18 (Scheme 2) in 74% yield. As with
the synthesis of the reference compound 6, the next alkylation
step used the same previously made bromide intermediate 11
with KHMDS to yield 19. The crude product was similarly cy-
clised using zinc chloride in diethyl ether, to give 20 with 85%
yield. Ester 20 was then hydrolysed using sodium hydroxide in
ethanol and water to give acid 21. Although the two-step
amide formation via the acid chloride intermediate was suc-
cessfully used in the synthesis of the reference compound 6,
here we found that a one-step HOBt/EDCI amide coupling was
more efficient for the synthesis, yielding 22. The reaction uti-
lises two activated ester derivatives as intermediates, regener-
ating HOBt and giving urea as a byproduct. However, on a
larger scale this route was not so efficient due to formation of
homocoupled byproducts. Compound 22 was dehalogenated
in the presence of H2 on Pd/C under basic conditions (triethyla-
mine) to give product 23. A second hydrogenation on crude
23 in the absence of triethylamine was performed to remove
the benzyl protecting group to give crude 24 in quantitative
yield. Using crude alcohol 24, we prepared both crude tosylate
25 and crude mesylate precursor 26 (Scheme 3) in a reaction
with tosyl or mesyl chloride, with 13 and 12% yield over five
steps, respectively. Tosyl analogue 25 was successfully purified
by recrystallisation from EtOAc to give a crystalline solid (33%).
However, the mesyl precursor 26 required purification by
column chromatography, yielding a viscous oil (37%), thus
making tosyl precursor 25 practically easier to purify and
handle than the mesyl precursor 26.
Because it is well known that enantiomers may have differ-
ent pharmacokinetic, pharmacodynamic, and safety/toxicity
profiles, we also aimed to investigate the difference between
Scheme 1. Synthesis of reference compound 6 : a) TsCl, pyridine, 23 8C, 18 h,
26%; b) 8, NaH, DMF, 100 8C, 18 h, 32%; c) KHMDS, THF, 23 8C, 4 h; d) ZnCl2,
Et2O, reflux, 16 h, 31%; e) H2, Pd/C, EtOH, 23 8C, 18 h; f) NaOH, H2O, EtOH,
reflux, 18 h; g) (COCl)2, DMF, 23 8C, 2 h; h) CH2Cl2, 23 8C, 18 h, 28% (over four
steps).
Scheme 2. Syntheses of radiolabelling precursors 25 and 26 : a) NaBH(OAc)3,
CH2Cl2, 23 8C, 18 h, 74%; b) KHMDS, THF, 23 8C, 1.5 h; c) ZnCl2, Et2O, reflux,
5 days, 85% (over two steps) ; d) NaOH, H2O, EtOH, 80 8C, 18 h; e) HOBt,
EDCI, 23 8C, 48 h; f) H2, Pd/C, MeOH, Et3N, 23 8C, 18 h; g) H2, Pd/C, MeOH,
23 8C, 18 h.
Scheme 3. Completion of the syntheses of radiolabelling precursors 25 and
26 : a) TsCl, DMAP, pyridine, 23 8C, 18 h, 13% (over five steps) ; b) MsCl, Et3N,
CH2Cl2, 23 8C, 18 h, 12% (over five steps).
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the two enantiomers of [18F]6 by establishing the chiral separa-
tion of both reference compound 6 as well as its radiolabelling
precursor (25). A clear choice for chiral separation was found
in the preparation of diastereomeric mixture by application of
a chiral derivatisation group. We identified an acid intermedi-
ate 21 for further functionalisation with several potential enan-
tiomerically pure alcohols. The alcohols selected were l-men-
thol, (R)-(@)-2-butanol, and (R)-1-phenyl-2-propyn-1-ol. The
ester 28 with (R)-(@)-2-butanol was formed in 53% yield using
DBU as a base and a mesylate analogue 27 of the alcohol as
an intermediate. However, a higher-yielding and a more direct
method of EDCI/DMAP coupling was used to form the esters
with l-menthol and (R)-1-phenyl-2-propyn-1-ol, which afforded
29 and 30 in 54 and 31% yields, respectively (Scheme 4).
While NMR analysis demonstrated the presence of two dia-
stereomers in all three product mixtures, TLC analysis of the
ester mixtures using a variety of solvent systems showed the
two diastereomers could be separated readily by flash column
chromatography in two cases, that of l-menthol and (R)-1-
phenyl-2-propynyl analogues. Flash chromatography using di-
ethyl ether and cyclohexane yielded two diasteriomerically en-
riched samples with both esters 29 (in 78 and 40% diastereo-
meric excess) and 30 (in 82 and 35% diastereomeric excess)
(Scheme 4; (S,L)-29, (R,L)-29 and (S,R)-30, (R,R)-30). To demon-
strate the presence of a single enantiomer in a mixture, the
chiral l-menthol functionality was first removed under a variety
of basic conditions (Table 1). LC–MS analysis showed near-com-
plete transformation with NaOH/H2O in EtOH (entry 1), which
were the hydrolytic conditions used in the synthesis of the ref-
erence compound 6 and precursors 25 and 26. Reaction with
Scheme 4. Separation of enantiomers using derivatisation method with chiral alcohols : a) EDCI, DMAP, CH2Cl2, 23 8C, 16 h, 54%; b) EDCI, DMAP, CH2Cl2, 23 8C,
4 h, 31%; c) DBU, toluene, 80 8C, 4 h; d) EDCI, DMAP, CH2Cl2, 23 8C, 16 h, 54%; e) CuCl, MeOH, 40 8C, 6 h.
Table 1. Conditions for the removal of chiral functionality.
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LiOH in a mixture of THF/H2O (entry 2) gave a minor byprod-
uct.[17]
Using K2CO3 in MeOH (entry 3) gave an equal amount of the
desired product and an unidentified byproduct,[18] while reac-
tion with trimethyltin hydroxide (entry 4) showed an incom-
plete reaction (63% by LC) even when the reaction time was
increased.[19] To assess the enantiomeric purity of the product
formed, diastereomerically enriched acid was re-esterified with
l-menthol using EDCI/DMAP. To our disappointment, 1H NMR
analysis indicated complete racemisation from all investigated
hydrolytic reaction conditions. This was further confirmed by
chiral HPLC analysis of the acid samples obtained from hydrol-
ysis of diastereomerically enriched ester samples (e.g. , (S)-21,
Scheme 4). Poor stability of the acid 21 in a solution presuma-
bly due to the presence of a highly acidic proton is a likely ex-
planation for such rapid racemisation of the stereocenter. In
the case of the ester analogue 30, while we were able to
obtain diastereomerically enriched samples through multiple
rounds of flash column chromatography in diastereomeric
excess ((S,R)-30, (R,R)-30), a previously described CuCl hydroly-
sis protocol failed to give the enantiomerically enriched prod-
uct 21 (Scheme 3).[20] Faced with the immediate need to have
reference material and precursor separated into enantiomers,
we turned to a commercial partner who performed enantiomer
separation successfully using SFC for both reference com-
pound 6 and tosylate 25 (see the Supporting Information for
details).
Absolute stereochemistry of enantiomers
The absolute stereochemistry of enantiomers of 6 was next de-
termined by electronic circular dichroism (CD) spectroscopy
whereby CD spectra of 6 were compared with that of 5, for
which stereochemistry had already been established (Figure 3).
The spectrum of known (S)-5 was composed of a maximum
positive Cotton effect at 200 nm and a corresponding maxi-
mum negative Cotton effect at 226 nm. The enantiomer of 6,
which similarly exhibited a maximum positive Cotton effect at
204 nm and a corresponding maximum negative Cotton effect
at 228 nm, was in analogy assigned as the S isomer. The other
isomer showed the mirror image bisignate band in the CD
spectrum and was therefore identified as R enantiomer.[21]
To correlate enantiomers obtained via SFC separation to CD
data, the chiral HPLC separation was performed on a Whelk-O1
column to unambiguously identify first eluting peak as the
S enantiomer (Supporting Information).
Assessment of GE387 binding affinity to Ala147Thr TSPO
Using an assay based on human embryonic kidney cell lines
stably overexpressing human TSPO wild-type and TSPO
A147T[13] compound 5 was shown to bind to wild-type TSPO
with a higher affinity than compound 1, but lost affinity at
A147T TSPO (Table 2). Compound (S)-6 bound to wild-type
TSPO with a similar affinity to compound 1, and both com-
pounds 1 and (S)-6 only showed minor loss in affinity at A147T
TSPO (1.2–1.3V reduction; Table 2). It has been shown for this
assay that compounds have lower binding affinities than those
commonly reported at rat TSPO. This is also shown for (S)-6 :
36.3 nm, while 1.04 nm for rat TSPO.[14]
Radiochemistry
To establish suitable reaction conditions for radiolabelling of
[18F]5, manual radiochemical reactions were performed first.
Both precursors 25 and 26 were assessed and the effect of
temperature, solvent, and time was investigated (Table 3). For
all reactions using 25 (entries 1–6), a single radiolabelled prod-
uct formed which was identified as [18F]6 via co-injection of
reference compound 6. However, when using 26 (entries 7–
12), a second unidentified radiolabelled product was formed
during the reaction. The amount of this radiolabelled side
product which formed immediately, did not change during the
course of the reaction.
At 80 8C, independent of solvent and precursor, low conver-
sion of <20% of [18F]fluoride to [18F]6 was observed: the high-
est being 18% when MeCN was used as a solvent and mesy-
late 25 as a precursor. When the temperature was increased to
100 8C or 120 8C reactions performed in DMF similarly showed
poor conversion (entries 6 and 12) after 20 min. In DMSO,
[18F]6 formed with 3% conversion after 20 min (entry 10) when
Figure 3. CD spectral data for (R)-6 and (S)-6 and comparison with the
known CD spectrum of (S)-5.
Table 2. Binding affinities (Ki) for wild-type and A147T TSPO.
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26 was used as precursor, whereas tosylate 25 afforded 47%
conversion into [18F]6 under analogous conditions (entry 4).
The highest conversion in the case of both precursors 25 and
26 was observed after 20 min in MeCN: 81 and 39%, respec-
tively (entries 2 and 8).
With this result in hand (MeCN as a solvent, 100 8C, 20 min),
next tosylate 25 was used for automated radiolabelling on a
GE Healthcare FXFN TRACERlab instrument. [
18F]Fluorination
was achieved with cyclotron-produced [18F]fluoride in MeCN at
100 8C for 20 min. Product [18F]6 was purified by semiprepara-
tive reversed-phase HPLC.
Total radiosynthesis time for the preparation for [18F]6 was
60 min from end of bombardment (EOB). Radiochemical purity
was over 99%, and radiolabelling yield was 20.8:4.5% decay-
corrected to EOB or 13.6:2.8% non-decay-corrected, and
molar radioactivity 93.2:50.6 GBqmmol@1 (n=9) at the end of
synthesis (EOS). Furthermore, the same automated protocol
was used for the radiosyntheses of (R)-[18F]6 and (S)-[18F]6 as
follows: 21.3:16.7 and 25.6:7.1% decay-corrected yields, ra-
diochemical purity >98% and molar radioactivities 55.8:35.6
and 63.5:39.5 GBqmmol@1 (n=3) at the EOS, respectively.
In vivo PET analysis
As a proof-of-principle of our novel radiotracer candidate we
next performed PET scans in male Wistar rats to establish that
racemic [18F]6 enters the brain (Figure 4). The time–activity
curve indicates distribution of radioactivity in the brain, albeit
in a modest amount as the investigated animals were healthy.
Conclusions
Herein we investigated the synthesis of a novel TSPO radiotrac-
er [18F]6, which has high binding affinity for TSPO. Critically we
have established that compound 6 has low sensitivity to the
human gene polymorphism rs6971. Based on the synthetic se-
quence of an analogue [18F]5, we synthesised the racemate of
reference compound 6 and appropriate radiolabelling precur-
sors 25 and 26 for radiolabelling with fluorine-18. We then ex-
plored chiral resolution using the formation of diastereomeric
mixtures, but were met with disappointing results. With the
racemic precursors in hand, we then optimised radiolabelling
conditions under manual reaction conditions and subsequently
established the automatic radiolabelling conditions to form
both racemic and enantiomerically pure isomers of [18F]6. The
PET scans performed indicate that racemic [18F]6 enters the
brain. Detailed studies of biological evaluation of each of the
enantiomers of [18F]6 are currently ongoing in our laboratory
and will be reported in due course.
Table 3. Screened reaction conditions for radiolabelling of [18F]6.
Figure 4. a) Time–activity curve (TAC, n=2) over the acquisition time of
60 min and b) summed 30–60 min PET image of racemic [18F]6 in a healthy
rat.




All reactions requiring anhydrous conditions were conducted in
oven-dried glass apparatus under an atmosphere of inert gas. Re-
agents were purchased from Sigma–Aldrich or Alfa Aesar. Reagents
were used without further purification unless otherwise noted.
Triethylamine (Et3N) was distilled over P2O5 and stored over KOH.
Reported density values are for ambient temperature. Purity of
compounds was +95% as determined by analytical HPLC on a
Thermo Dionex 3000 HPLC system. Preparative chromatographic
separations were performed on Material Harvest silica gel 60 (35–
75 mm) and reactions followed by TLC analysis using Sigma–Aldrich
silica gel 60 plates (2–25 mm) with fluorescent indicator (254 nm)
and visualised with UV or potassium permanganate.
1H NMR spectra were recorded in Fourier transform mode using a
Bruker Avance III 300 MHz FT NMR spectrometer and the data
were analysed using TopSpin software. Spectra were obtained
from the specified deuterated solvents in 5 mm diameter tubes.
Chemical shifts in ppm are quoted relative to residual solvent sig-
nals calibrated as follows: CDCl3 dH (CHCl3)=7.26 ppm, dC=
77.2 ppm. Multiplicities in the 1H NMR spectra are described as: s=
singlet, d=doublet, t= triplet, q=quartet, quint.=quintet, s=
sextet, h=heptet, m=multiplet, b=broad; coupling constants are
reported in Hz.
LC–MS data were obtained using a Waters Acquity-H/Xevo TQD
LC–MS instrument. Column: Acquity UPLCS BEH C18 1.7 mm, 2.1V
50 mm; flow rate: 0.6 mLmin@1, 4 min method, 5–95% MeCN/H2O
with 0.1% formic acid. HRMS data were obtained from the EPSRC
Mass Spectrometry Service at the University of Swansea. Ion mass/
charge (m/z) ratios are reported as values in atomic mass units.
The automated radiosynthesis was performed on a GE Healthcare
FXFN TRACERlab. Semipreparative purification of radiolabelled ma-
terial was performed on a Merck-Hitachi L6200A system equipped
with Knauer variable wavelength detector and an Eberline radia-
tion detector using a reversed-phase column (ACE 160433, C18,
5 mm, 100V10 mm) and eluting with 48% aq. MeCN at a flow rate
of 5 mLmin@1. Analytical HPLC samples were analysed by an Agi-
lent HPLC 1100 system equipped with UV multi-wavelength detec-
tor and Raytest Gabi star radiation detector using reversed-phase
column (Phenomenex Luna 5 mm C18 (2) 100 a, 250V4.6 mm,
675295-11) and eluting with 0–3 min isocratic 10% aq. MeCN, 3–
5 min gradient 10–80% aq. MeCN, 6–12 min isocratic 80% aq.
MeCN at a flow rate of 1.5 mLmin@1.
Chemistry
2-Fluoroethyl 4-methylbenzenesulfonate (8). Commercially avail-
able 2-fluoroethanol 7 (0.141 mL, 153 mg, 2.40 mmol, 1 equiv, d=
1.09 gcm@3) was dissolved in pyridine (2.5 mL) under nitrogen. The
solution was stirred at 0 8C and tosyl chloride (1.00 g, 5.25 mmol,
2.2 equiv) added portion-wise to the solution over a period of
30 min, keeping the temperature below 5 8C. The reaction was
stirred at RT for 18 h. The reaction was then quenched by careful
addition of ice followed by water (5 mL). The reaction mixture was
extracted into EtOAc (10 mL) and washed with water (3V10 mL),
1m HCl solution (10 mL), 1m aqueous sodium carbonate (10 mL),
and copper sulfate (2V10 mL). The organic layer was washed with
brine (10 mL), dried (MgSO4) and concentrated in vacuo to give 8
as an oil (136 mg, 0.62 mmol, 26%). LC–MS: Rf 1.86 (@ESI) m/z
311.5 ([M+94]+) ; 1H NMR (300 MHz, CDCl3): dH=7.81 (2H, d, J=
8 Hz, SO2CCHCH), 7.36 (2H, d, J=8 Hz, SO2CCHCH), 4.57 (2H, ddd,
J=3 and 50 Hz, OCH2CH2F), 4.26 (2H, ddd, J=4 and 30 Hz,
OCH2CH2F), and 2.45 (3H, s, CCH3). Characterization data for this
compound are in complete agreement with previously published
data.[16]
2-Chloro-N-(2-fluoroethyl)-5-methoxyaniline (10). Commercially
available 2-chloro-5-methoxyaniline hydrochloride 9 (5.00 g,
26 mmol, 1 equiv) was dissolved in DMF (60 mL) and sodium hy-
dride (60% dispersion in mineral oil, 2.30 g, 57 mmol, 2.2 equiv)
was added. The reaction was stirred for 30 min at RT under nitro-
gen. The tosylate 8 (6.00 g, 31 mmol, 1.2 equiv) in DMF was then
added dropwise and the reaction was stirred at RT for 2 h. The re-
action was then heated at 100 8C for 18 h. The reaction was al-
lowed to cool and the solvent was removed under reduced pres-
sure. The residue was dissolved in EtOAc (100 mL) and washed
with water (5V100 mL). The organic layers were combined, dried
(MgSO4) and concentrated in vacuo to give a brown oil. The crude
mixture was then purified by silica flash chromatography eluting
with a gradient of 5–30% EtOAc/petroleum ether (40–60 8C) to
yield 10 as a yellow oil (1.69 g, 8.32 mmol, 32%). LC–MS: Rf 2.01 (+
ESI) m/z 204.3 ([M+H]+) ; 1H NMR (300 MHz, CDCl3): dH=7.16 (1H,
dm, J=5 Hz, CHC(OCH3)CHCH), 6.25–6.22 (2H, m,
CHC(OCH3)CHCH), 4.64 (2H, dt, J=5 and 47 Hz, NCH2CH2F), 4.65–
4.55 (1H, b, NH), 3.77 (3H, s, OCH3), and 3.48 (2H, dq, J=5 and
26 Hz, NCH2CH2F). Characterization data for this compound are in
complete agreement with an internal GE publication.[14]
Ethyl 3-bromo-2-hydroxycyclohex-1-ene-1-carboxylate (11). Ethyl
2-oxocyclohexanecarboxylate S1 was dissolved in diethyl ether and
cooled to 0 8C under nitrogen. Bromine was added dropwise over
15 min and the reaction mixture was allowed to warm to RT over
90 min. The mixture was slowly poured into ice-cold saturated
aqueous potassium carbonate and extracted with ethyl acetate.
The combined organic layers were dried over magnesium sulfate,
filtered, concentrated in vacuo and dried on the vacuum line for
18 h to afford 11 as a yellow oil. LC–MS: Rf 2.17;
1H NMR (300 MHz,
CDCl3): dH=11.92 (1H, s, OH), 4.93 (1H, t, J=3.4 Hz, BrCHC(OH)),
4.20 (2H, ddd, J=1, 7 and 14 Hz, C(O)OCH2CH3), 2.53–2.46 (2H, m,
BrCHCH2CH2CH2), 2.12–2.03 (2H, m, BrCHCH2CH2CH2), 1.79–1.67
(2H, m, BrCHCH2CH2CH2), 1.24 (3H, t, J=7 Hz, C(O)OCH2CH3). Char-
acterization data for this compound are in complete agreement
with an internal GE publication.[14]
Ethyl-3-((2-chloro-5-methoxyphenyl)(2-fluoroethyl)amino)-2-hy-
droxycyclohex-1-ene-1-carboxylate (12). A solution of the aniline
10 (2.20 g, 10.8 mmol, 1 equiv) in THF (60 mL) was cooled to
@40 8C. Potassium bis(trimethylsilyl)amide (0.5m solution in tolu-
ene, 45.4 mL, 4.5 g, 22.7 mmol, 2.1 equiv) was added dropwise and
the reaction stirred for 30 min at @40 8C. The carboxylate 11
(2.67 g, 10.8 mmol, 1 equiv) in THF (10 mL) was added dropwise at
@40 8C. The cooling bath was removed and the reaction was
stirred at RT for 4 h. The reaction was quenched with brine
(100 mL) and extracted into EtOAc (2V200 mL), dried (MgSO4) and
concentrated in vacuo to give 12 as a brown oil (3.70 g,
9.97 mmol) which was used crude in the next step. LC–MS: Rf 2.29
(+ESI) m/z 372.4 ([M+H]+). Characterization data for this com-
pound are in complete agreement with an internal GE publica-
tion.[14]
Ethyl 8-chloro-9-(2-fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-
1H-carbazole-4-carboxylate (13). The intermediate 12 (3.71 g,
10.0 mmol, 1 equiv) was dissolved in Et2O (100 mL) and zinc chlo-
ride (5.45 g, 40.0 mmol, 4 equiv) was added. The reaction was
heated at reflux for 16 h. EtOAc (300 mL) was added to dissolve ev-
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erything and was washed with 2m HCl (200 mL), water (200 mL),
10% aqueous potassium carbonate (200 mL), dried (MgSO4) and
concentrated in vacuo. The crude material was purified by silica
gel chromatography eluting with a gradient of 5–20% of EtOAc/
petroleum ether (40–60 8C) to afford 13 as a yellow oil (1.1 g,
3.12 mmol, 31% over two steps). Material could not be obtained in
a pure form, but regardless, the reaction was progressed to the
next step. LC–MS: Rf 2.38 (+ESI) m/z 354.4 ([M+H]
+) ; 1H NMR
(300 MHz, CDCl3): dH=6.95 (1H, d, J=8 Hz, 7-CH), 6.35 (1H, d, J=
8 Hz, 6-CH), 4.90–4.40 (4H, m, NCH2CH2F, NCH2CH2F), 4.20–4.10 (3H,
m, 4-CH, CO2CH2CH3), 2.80–2.65 (2H, m, 1-CH2), 3.79 (3H, s, OCH3),
2.10–1.80 (4H, m, 2- and 3-CH2), and 1.30–1.20 (3H, m, CO2CH2CH3).
Characterization data for this compound are in complete agree-
ment with an internal GE publication.[14]
Ethyl 9-(2-fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carba-
zole-4-carboxylate (14). The chloro intermediate 13 (1.10 g,
3.11 mmol, 1 equiv) was dissolved in methanol (50 mL) and triethyl-
amine (0.517 mL, 377 mg, 3.73 mmol, 1.2 equiv, d=0.73 gcm@3)
and 10% Pd/C (0.414 g) were added. The mixture was stirred for
18 h after purging twice (over 2 h) with hydrogen gas under at-
mospheric pressure. The reaction was filtered through a pad of
Celite under nitrogen atmosphere, washed with methanol (50 mL),
and the solvent was removed in vacuo. The residue was dissolved
in EtOAc (100 mL) and washed with 10% aqueous potassium car-
bonate (100 mL), dried (MgSO4) and concentrated in vacuo to give
14 as an oil (0.75 g, 2.35 mmol, 76%). LC–MS: Rf 2.18 (+ESI) m/z
320.5 ([M+H]+ , 43%), Rf 2.20 (@ESI) m/z 318.4 ([M@H]@) ; 1H NMR
(300 MHz, CDCl3): dH=7.04 (1H, t, J=8 Hz, 7-CH), 6.84 (1H, d, J=
8 Hz, 8-CH), 6.46 (1H, d, J=8 Hz, 6-CH), 4.64 (2H, dm, J=47 Hz,
NCH2CH2F), 4.40–4.00 (5H, m, 4-CH, CO2CH2CH3, NCH2CH2F), 3.82
(3H, s, OCH3), 2.90–2.60 (2H, m, 1-CH2), 2.20–1.80 (4H, m, 2- and 3-
CH2), and 1.30–1.20 (3H, m, CO2CH2CH3). Characterization data for
this compound are in complete agreement with an internal GE
publication.[14]
9-(2-Fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-
carboxylic acid (15). The ester 14 (0.747 g, 2.34 mmol, 1 equiv)
was dissolved in ethanol (10 mL). A solution of sodium hydroxide
(1.13 g, 28.2 mmol, 12 equiv) dissolved in 10 mL of water, was
added. The reaction mixture was heated at reflux for 18 h. The sol-
vent was removed in vacuo and the crude mixture diluted with
water (30 mL), acidified with 2m HCl dropwise until acidic, and
washed with CH2Cl2 (50 mL). The organic layers were combined
and dried (MgSO4) and concentrated in vacuo to give 15 (0.66 g,
2.27 mmol), which was used crude into the next step. LC–MS: Rf
1.81 (+ESI) m/z 292.4 ([M+H]+).
9-(2-Fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-
carbonyl chloride (16). A solution of 15 (0.660 g, 2.27 mmol,
1 equiv) in anhydrous CH2Cl2 (5 mL) was stirred under nitrogen.
Oxalyl chloride (0.584 mL, 865 mg, 6.81 mmol, 3 equiv, d=
1.48 gcm@3) was added followed by a drop of DMF. The reaction
mixture was stirred at RT under nitrogen for 2 h then evaporated in
vacuo to give 16 (1.03 g, 3.33 mmol) as an oil, which was used into
the next step without purification.
N-Benzyl-N-ethyl-9-(2-fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-
1H-carbazole-4-carboxamide (GE387) (6). The acid chloride 16
(1.03 g, 3.33 mmol, 1 equiv) was dissolved in anhydrous CH2Cl2
(8 mL) and cooled to 0 8C. N-Ethylbenzylamine (0.977 mL, 901 mg,
6.67 mmol, 2 equiv, d=0.92 gcm@3) was then added and the reac-
tion was stirred for 18 h at RT. The reaction was quenched with
10% aqueous potassium carbonate (6 mL). The CH2Cl2 layer was
collected via a separatory funnel, dried (MgSO4), and then concen-
trated in vacuo. The crude material was purified by silica gel chro-
matography eluting with a gradient of 50–100% EtOAc/petroleum
ether (40–60 8C) to afford the crude product as a yellow oil. The oil
was then recrystallised from EtOAc to afford 6 as a pale-yellow
solid (350 mg, 0.86 mmol, 26% over two steps). LC–MS: Rf 2.30 (+
ESI) m/z 409.6 ([M+H]+ , 31%), Rf 2.35 (+ESI) m/z 409.6 ([M+H]
+) ;
1H NMR (300 MHz, CDCl3): dH=7.42–7.21 (5H, m, Ph), 7.02 (1H, t,
J=8 Hz, 7-CH), 6.84 (1H, d, J=8 Hz, 8-CH), 6.43 (1H, d, J=8 Hz, 7-
CH), 4.80–4.40 (3H, m, CH2CH2F, 4-CH), 4.31 (2H, dt, J=5 and 24 Hz
NCH2CH2F), 3.62 (3H, s, OCH3), 3.83–3.41 (4H, m, N(CH2CH3)2), 2.88–
2.61 (2H, m, 1-CH2), 2.20–1.80 (4H, m, 2- and 3-CH2), and 1.32 (3H,
t, J=7 Hz, N(CH2CH3)2).
N-(2-(Benzyloxy)ethyl)-2-chloro-5-methoxyaniline (18). Commer-
cially available 9 (11.7 g, 60.5 mmol, 1 equiv) was converted into
the free base with 1m aqueous sodium carbonate (300 mL). The
mixture was extracted with CH2Cl2 (2V200 mL), the organic layer
dried (MgSO4) and evaporated to give an oil. Compound 9 was
then dissolved in CH2Cl2 (50 mL), in a dry flask under nitrogen. Ben-
zyloxyacetaldehyde 17 (9.36 mL, 10.0 g, 66.6 mmol, 1.1 equiv, d=
1.07 gcm@3) and acetic acid (3.81 mL, 4.0 g, 66.6 mmol, 1.1 equiv,
d=1.05 gcm@3) were added. After 15 min sodium triacetoxyboro-
hydride (19.3 g, 90.8 mmol, 1.5 equiv) was added. The mixture was
stirred for 18 h at RT and then poured into saturated aqueous am-
monium chloride solution (100 mL) and extracted with CH2Cl2 (2V
100 mL). The combined organic layers were dried (MgSO4) and
evaporated to give an oil. The crude product was purified via silica
flash chromatography eluting with CH2Cl2 to yield 18 as an oil
(13.0 g, 44.8 mmol, 74%). Material could not be obtained in a pure
form, but regardless, the reaction was progressed to the next step.
LC–MS: Rf 2.42 (+ESI) m/z 292.3 ([M+H]
+) ; 1H NMR (300 MHz,
CDCl3): dH=7.37–7.30 (5H, m, Ph), 7.14 (1H, d, J=8 Hz,
CHC(OCH3)CHCH), 6.23–6.18 (2H, m, CHC(OCH3)CHCH), 4.71 (2H, s,
OCH2Ph), 3.74 (3H, s, OCH3), 3.73 (2H, t, J=5 Hz, CH2O), and 3.35
(2H, dd, J=6 Hz, CH2N). Characterization data for this compound
are in complete agreement with an internal GE publication.[14]
Ethyl 3-((2-(benzyloxy)ethyl)(2-chloro-5-methoxyphenyl)amino)-
2-hydroxycyclohex-1-ene-1-carboxylate (19). The aniline 18
(14.1 g, 48.5 mmol, 1 equiv) was stirred in dry THF (150 mL) at
@40 8C under nitrogen and potassium bis(trimethylsilyl) amide
(0.5m solution in toluene, 203 mL, 20.2 g, 101.9 mmol, 2.1 equiv)
was added over 30 min. The carboxylate 11 (12.0 g, 48.5 mmol,
1 equiv) in dry THF (50 mL) was then added and allowed to warm
to RT over a period of 1.5 h. Acetic acid was added (15 mL) and
concentrated in vacuo to remove the THF. EtOAc (200 mL) and
10% aqueous potassium carbonate (200 mL) was added and the
mixture vigorously shaken. The EtOAc solution was separated,
dried over (MgSO4) and concentrated in vacuo to afford 19 as an
oil (24.0 g, 52.2 mmol), which was used crude in the next step. LC–
MS: Rf 2.39 (@ESI) m/z 458.5 ([M@H]@), Rf 2.53 (+ESI) m/z 460.5
([M+H]+), Rf 2.39 (+ESI) m/z 460.5 ([M+H]
+). Characterization
data for this compound are in complete agreement with an inter-
nal GE publication.[14]
Ethyl 9-(2-(benzyloxy)ethyl)-8-chloro-5-methoxy-2,3,4,9-tetrahy-
dro-1H-carbazole-4-carboxylate (20). Zinc chloride (19.6 g,
144 mmol, 3 equiv) was added to carboxylate 19 (22.0 g,
48.0 mmol, 1 equiv) in dry Et2O (400 mL) under nitrogen and
heated at reflux for 5.5 h. As the reaction was held at reflux, a thick
brown dense oil formed in the reaction. The reaction was then
cooled and the supernatant Et2O decanted off, EtOAc (300 mL) was
added, washed with 2m HCl (150 mL) and with 10% aqueous po-
tassium carbonate (150 mL). The EtOAc layer was separated, dried
(MgSO4) and concentrated in vacuo to afford an oil. The crude ma-
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terial was purified by silica gel chromatography eluting with a gra-
dient of 10–40% EtOAc/petroleum ether (40–60 8C) to afford 20 as
an oil (1.98 g, 4.49 mmol). The thick dense brown layer was treated
with EtOAc (300 mL) and 2m HCl (150 mL). The EtOAc layer was
separated, washed with 10% aqueous potassium carbonate
(150 mL), dried (MgSO4) and concentrated in vacuo to give an oil.
Et2O (400 mL) and anhydrous zinc chloride (19.6 g, 144 mmol,
3 equiv) were added. The mixture was heated at reflux for a further
5 days. The Et2O layer and the dark gum were both diluted with
EtOAc (200 mL) and then washed with 2m HCl (150 mL), dried
(MgSO4) and concentrated in vacuo to give a gum. This gum was
purified by silica gel chromatography eluting with a gradient of 5–
35% EtOAc/petroleum ether (40–60 8C) to afford 20 as an oil
(16.1 g, 36.5 mmol, 85% total over two steps). LC–MS: Rf 2.66 (+
ESI) m/z 442.5 ([M+H]+) ; 1H NMR (300 MHz, CDCl3): dH=7.31–7.16
(5H, m, Ph), 6.93 (1H, d, J=8 Hz, 7-CH2), 6.34 (1H, d, J=8 Hz, 6-
CH2), 4.58 (2H, dm, J=62 Hz, NCH2CH2O), 4.40 (2H, s, OCH2Ph),
4.20–4.09 (3H, m, CO2CH2CH3 and 4-CH), 3.86–3.80 (2H, m,
CH2OBn), 3.79 (3H, s, OCH3), 2.82–2.63 (2H, m, 1-CH2), 2.10–1.80
(4H, m, 2- and 3-CH2), and 1.23 (3H, t, J=7 Hz, CO2CH2CH3). Char-
acterization data for this compound are in complete agreement
with an internal GE publication.[14]
9-(2-(Benzyloxy)ethyl)-8-chloro-5-methoxy-2,3,4,9-tetrahydro-
1H-carbazole-4-carboxylic acid (21). To the ester 20 (0.401 g,
0.909 mmol, 1 equiv) in ethanol (12 mL) was added sodium hydrox-
ide (0.240 g, 6.00 mmol, 6.6 equiv) in water (1 mL) and heated at
80 8C for 18 h. The ethanol was then removed by evaporation in
vacuo and the residue partitioned between Et2O (30 mL) and water
(30 mL). The Et2O layer was separated, dried (MgSO4) and concen-
trated in vacuo to give a gum. The aqueous layer was acidified to
pH 1 with 2m HCl dropwise and extracted with CH2Cl2 (3V20 mL).
The organic layers were dried (MgSO4) and concentrated in vacuo
to afford 21 as a solid (0.36 g, 0.87 mmol, 93%). LC–MS: Rf 2.34 (+
ESI) m/z 414.4 ([M+H]+) ; 1H NMR (300 MHz, CDCl3): dH=7.31–7.15
(5H, m, Ph), 6.97 (1H, d, J=8 Hz, 7-CH), 6.41 (1H, d, J=8 Hz, 6-CH),
4.68–4.52 (2H, m, NCH2CH2O), 4.40 (2H, s, OCH2Ph), 4.18 (1H, t, J=
3 Hz, 4-CH), 3.88 (3H, s, OCH3), 3.82 (2H, t, J=6 Hz, CH2OBn), 2.86–
2.63 (2H, m, 1-CH2), and 2.27–1.86 (4H, m, 2- and 3-CH2). Character-
ization data for this compound are in complete agreement with an
internal GE publication.[14]
N-Benzyl-9-(2-(benzyloxy)ethyl)-8-chloro-N-ethyl-5-methoxy-
2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide (22). The acid 21
(2.23 g, 5.40 mmol, 1 equiv) was dissolved in THF (135 mL) under
N2 at RT. The solution was allowed to cool to 0 8C and N-ethylben-
zylamine (0.870 mL, 803 mg, 5.94 mmol, 1.1 equiv, d=0.92 gcm@3)
was added followed by 1-hydroxybenzotriazole hydrate (0.802 g,
5.94 mmol, 1.1 equiv) and N-(3-dimethylaminopropyl)-N’-ethylcar-
bodiimide hydrochloride (2.07 g, 10.8 mmol, 2 equiv). Finally, trie-
thylamine (2.99 mL, 2.18 g, 10.8 mmol, 4 equiv, d=0.73 gcm@3) was
added via syringe and the mixture stirred under N2 and warmed to
RT over 48 h. The reaction was then diluted with EtOAc (100 mL)
and filtered through Celite. The Celite was washed with more
EtOAc (2V100 mL). The combined filtrates were washed with 1m
aqueous HCl (2V150 mL), H2O (2V150 mL), brine (150 mL), dried
(MgSO4) and concentrated in vacuo to give the product 22 as an
oil (1.55 g, 2.92 mmol, 54%), which was used crude in the next
step. LC–MS: Rf 2.74 (+ESI) m/z 531.6 ([M+H]
+).
N-Benzyl-9-(2-(benzyloxy)ethyl)-N-ethyl-5-methoxy-2,3,4,9-tetra-
hydro-1H-carbazole-4-carboxamide (23). The carboxamide 22
(1.50 g, 2.83 mmol, 1 equiv) in methanol (120 mL) was shaken with
10% palladium on charcoal (1.5 g), triethylamine (0.549 mL,
401 mg, 3.96 mmol, 1.4 equiv, d=0.73 gcm@3) and stirred for 18 h
at RT after purging twice (over 2 h) with hydrogen gas under at-
mospheric pressure. The reaction was then filtered through a pad
of Celite under nitrogen atmosphere and the filtrate concentrated
in vacuo. The concentrate was then taken up in CH2Cl2 (200 mL)
and washed with 5% aqueous potassium carbonate solution
(200 mL). The CH2Cl2 solution was then separated, dried (MgSO4)
and concentrated in vacuo to afford 23 as an oil (1.10 g,
2.22 mmol), which was used crude in the next step. LC–MS: Rf 2.62
(+ESI) m/z 497.5 ([M+H]+).
N-Benzyl-N-ethyl-9-(2-hydroxyethyl)-5-methoxy-2,3,4,9-tetrahy-
dro-1H-carbazole-4-carboxamide (24). The benzyl-protected inter-
mediate 23 (1.10 g, 2.22 mmol, 1 equiv) in methanol (50 mL) was
shaken with 10% palladium on charcoal (0.333 g) and stirred for
18 h at RT after purging twice (over 2 h) with hydrogen gas under
atmospheric pressure. The reaction was then filtered through a
pad of Celite under nitrogen atmosphere and the filtrate concen-
trated in vacuo to give 24 as an oil (900 mg, 2.22 mmol), which
was used crude in the next step. LC–MS: Rf 2.08 (+ESI) m/z 407.5
([M+H]+).
2-(4-(Benzyl(ethyl)carbamoyl)-5-methoxy-1,2,3,4-tetrahydro-9H-
carbazol-9-yl)ethyl4-methylbenzenesulfonate (25). The alcohol
24 (500 mg, 1.23 mmol, 1 equiv) was dissolved in anhydrous pyri-
dine (5 mL) under N2. The solution was cooled to 0 8C and 4-tolue-
nesulfonyl chloride (515 mg, 2.71 mmol, 2.2 equiv) added potion-
wise to the solution over 30 min. 4-Dimethylaminopyridine
(15.0 mg, 0.123 mmol, 0.1 equiv) was then added, and the solution
was stirred and warmed to RT for 18 h. The reaction was then
quenched by careful addition of ice followed by water (5 mL). The
mixture was then extracted into EtOAc and washed with water (3V
10 mL). Excess pyridine was removed by washing with 1m HCl (2V
10 mL) and aqueous copper sulfate (2V10 mL). Excess 4-toluene-
sulfonyl chloride was removed by washing with 1m aqueous
sodium carbonate (2V10 mL). The organic layer was washed with
brine (10 mL), dried (MgSO4) and concentrated in vacuo. The crude
product was recrystallised from EtOAc to afford 25 as an off-white
solid (220 mg, 0.40 mmol, 33%). LC–MS: Rf 2.46 (+ESI) m/z 561.6
([M+H]+) ; 1H NMR (300 MHz, CDCl3): dH=7.51 ((2H, d, J=8 Hz,
SO2C(CH2)(CH2)CH3), 7.35–7.15 (5H, m, Ph), 7.09 (2H, d, J=8 Hz,
SO2C(CH2)(CH2)CH3), 6.91 (1H, t, J=8 Hz, 7-CH), 6.62 (1H, d, J=
8 Hz, 8-CH), 6.37 (1H, d, J=8 Hz, 6-CH), 4.70–4.50 (2H, m, CH2N),
4.30–4.15 (3H, m, 4-CH and CH2OH), 3.61 (3H, s, OCH3), 3.80–3.40
(4H, m, N(CH2)2), 2.80–2.50 (2H, m, 1-CH2), 2.33 (3H, s, SO2PhCH3),
2.1–1.60 (4H, m, 2- and 3-CH2), and 1.30 (3H, t, J=7 Hz, NCH2CH3).
2-(4-(Benzyl(ethyl)carbamoyl)-5-methoxy-1,2,3,4-tetrahydro-9H-
carbazol-9-yl)ethyl methanesulfonate (26). The phenol 24
(400 mg, 0.985 mmol, 1 equiv) in CH2Cl2 (20 mL) was cooled to 0 8C
and methanesulfonyl chloride (0.229 mL, 338 mg, 2.95 mmol,
3 equiv, d=1.48 gcm@3) and triethylamine (0.409 mL, 299 mg,
2.95 mmol, 3 equiv, d=0.73 gcm@3) were added and allowed to
warm to RT for 18 h. The reaction was diluted with CH2Cl2 (20 mL)
washed with 5% aqueous potassium carbonate solution (40 mL).
The layers were separated. The combined organic layers were
dried (MgSO4) and concentrated in vacuo to give a gum. The crude
material was purified by silica gel flash chromatography eluting
with a gradient of 50–100% EtOAc/petroleum ether (40–60 8C) to
afford 26 as an oil (142 mg, 0.29 mmol, 37%). LC–MS: Rf 2.12 (+
ESI) m/z 485.5 ([M+H]+). 1H NMR (300 MHz, CDCl3): dH=7.40–7.10
(5H, m, NCH2Ph), 7.03 (1H, t, J=8 Hz, 7-CH), 6.86 (1H, d, J=8 Hz,
8-CH), 6.44 (1H, d, J=8 Hz, 6-CH), 4.65–4.50 (2H, m, CH2N), 4.50–
4.45 (3H, m, 4-CH and CH2OH), 3.64 (3H, s, OCH3), 3.90–3.20 (4H,
m, N(CH2)2), 2.90–2.60 (2H, m, 1-CH2), 2.51 (3H, s, OSO2CH3), 2.30–
1.70 (4H, m, 2- and 3-CH2), and 1.31 (3H, t, J=7 Hz, NCH2CH3).




boxylate (29). To a stirring solution of 21 (300 mg, 0.726 mmol,
1 equiv) and l-menthol in CH2Cl2 (40 mL) at 0 8C was added N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride
(139 mg, 0.726 mmol, 1 equiv) and 4-Dimethylaminopyridine
(92.8 mg, 0.726 mmol, 1 equiv). Stirring was continued at RT for
16 h. After this period, H2O (100 mL) and CH2Cl2 (100 mL) were
added. The organic layer was washed with 1m HCl, saturated
NaHCO3 solution, and brine. The solution was dried (MgSO4), fil-
tered, and concentrated. The crude racemic mixture 29 (360 mg,
0.65 mmol) was separated into two diasteriomerically enriched
samples via silica flash chromatography eluting with 30% Et2O/cy-
clohexane. LC–MS: Rf 3.12 (+ESI) m/z 368.3 ([M@182]+ , 100%);
1H NMR (300 MHz, CDCl3): dH=7.36–7.12 (5H, m, Ph), 6.94 (1H, d,
J=8 Hz, 7-CH), 6.31 (1H, d, J=8 Hz, 6-CH), 4.90 (1H, dt, J=4 and
6 Hz, OCH), 4.38 (2H, d, J=6 Hz, NCH2CH2O), 4.09 (1H, t, J=6 Hz,
4-CH), 3.86–3.77 (2H, m, CH2OBn), 3.75 (3H, s, OCH3), 2.7–2.44 (3H,
m, 1-CH2, OCHCH2), 2.15–2.01 (1H, m, OCHCH2), 2.00–1.82 (3H, m,
2-CH2, OCHCH), 1.81–1.56 (4H, m, 3-CH2, CH3CH, OCHCHCH2), 1.46–
1.40 (12H, m, CH3CHCH2, OCHCHCH2, CHCH3, CH(CH3)2, and 1.02–
0.83 (1H, m, CH3CHCH2).
(R)-1-Phenylprop-2-yn-1-yl 9-(2-(benzyloxy)ethyl)-8-chloro-5-me-
thoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxylate (30). To a
solution of 21 (300 mg, 0.73 mmol, 1 equiv), N-(3-Dimethylamino-
propyl)-N’-ethylcarbodiimide hydrochloride (170 mg, 1.09 mmol,
1.5 equiv) and 4-Dimethylaminopyridine (6.96 mg, 0.04 mmol,
0.05 equiv) in CH2Cl2 (5 mL) was added (R)-1-phenyl-2-propyn-1-ol
(0.09 mL, 95.9 mg, 0.726 mmol, 1 equiv, d=1.07 gcm@3) at RT. The
reaction was stirred for 4 h at RT. The reaction mixture was diluted
with CH2Cl2 (20 mL) and washed with H2O (5 mL). The organic layer
was dried (MgSO4) and concentrated. The crude mixture was puri-
fied via silica flash column chromatography eluting with a gradient
of 20–40% Et2O/petroleum ether (40–60 8C) to yield 30 as a race-
mate (119 mg, 0.23 mmol, 31%). Separation of the two diastereo-
mer was done via silica flash column chromatography eluting with
a gradient of 10–20% Et2O/cyclohexane. LC–MS: Rf 2.72 (+ESI) m/z
528.5 ([M+H]+ , 28%), 2.73 (+ESI) m/z 528.5 ([M+H]+ , 51%);
1H NMR (300 MHz, CDCl3): dH=7.60–7.14 (10H, m, Ph, OCHPh), 6.90
(1H, d, J=8 Hz, 7-CH), 6.25 (1H, d, J=8 Hz, 6-CH), 4.71–4.53 (2H,
m, NCH2CH2O), 4.39 (1H, s, OCHPh), 4.15 (1H, t, J=6 Hz, 4-CH),
3.81 (2H, t, J=6 Hz, CH2OBn), 3.40 (3H, s, OCH3), 2.85–2.51 (2H, m,




1H-carbazole-4-carboxamide (6). 49.8 mg of a racemic mixture of
6 was sent to Reach Separations to be separated into the two
enantiomers. They provided the following methods for separation
and purification. The racemate 6 was dissolved to 12 mgmL@1 in
MeOH/CH2Cl2 (1:1) and was then purified by SFC using a Lux C1
column (21.2 mmV250 mm, 5 mm) at 40 8C and eluting with iso-
cratic 50:50 MeOH/CO2 with 0.2% v/v NH3 at a flow rate of
50 mLmin@1. The injection volume was 1500 mL and peaks were
detected at 223 nm. Combined fractions of each of the two enan-
tiomers were then evaporated to near dryness using a rotary evap-
orator, transferred into final vessels with CH2Cl2, which was re-
moved under a stream of compressed air at 40 8C before being
stored in a vacuum oven at 40 8C and 5 mbar for 4 h to afford the
two enantiomers as yellow gums. Chiral purity of the enantiomers
was analysed using a Lux C1 column (4.6 mmV250 mm, 5 mm) at
40 8C and eluting with isocratic 50:50 MeOH/CO2 with 0.2% v/v
NH3 at a flow rate of 4 mLmin
@1. The injection volume was 1.0 mL
and the peaks were detected at 210–400 nm. Chemical purity of
the enantiomers was analysed using an Acquity BEH C18 column
(50V2.1 mm, 1.7 mm) at 40 8C and eluting with 0–4 min gradient of
5–95% MeCN/H2O with 0.1% TFA, 4-4.02 min gradient of 95–100%
MeCN/H2O with 0.1% TFA, 4.03 min–4.5 min isocratic 100% MeCN
with 0.1% TFA, 4.5–4.52 min gradient of 100–5% MeCN/H2O with
0.1% TFA, and 4.53–6 min isocratic of 5% MeCN/H2O with 0.1%
TFA at flow rate of 0.6 mLmin@1. The injection volume was 1.0 mL
and the peak was detected at 220 nm. The final yield is 23.9 mg of
enantiomer (S)-6 with 98.02% chemical purity and in 100% ee, and
22.1 mg of enantiomer (R)-6 with 100% chemical purity and in
98.8% ee.
2-(4-(Benzyl(ethyl)carbamoyl)-5-methoxy-1,2,3,4-tetrahydro-9H-
carbazol-9-yl)ethyl 4-methylbenzenesulfonate (25). 162.4 mg of a
racemic mixture of 25 was sent to Reach Separations to be sepa-
rated into the two enantiomers. They provided the following meth-
ods for separation and purification. The racemate 25 was dissolved
to 23 mgmL@1 in MeOH/CH2Cl2 (1:1) and was then purified by SFC
using a Lux C1 column (21.2 mmV250 mm, 5 mm) at 40 8C and
eluting with isocratic 50:50 MeOH/CO2 with 0.2% v/v NH3 at a flow
rate of 50 mLmin@1. The injection volume was 1000 mL and peaks
were detected at 223 nm. Combined fractions of each of the two
enantiomers were then evaporated to near dryness using a rotary
evaporator, transferred into final vessels with CH2Cl2, which was re-
moved under a stream of compressed air at 40 8C before being
stored in a vacuum oven at 40 8C and 5 mbar for 4 h to afford the
two enantiomers as white solids. Chiral purity of the enantiomers
was analysed using a Lux C1 column (4.6 mmV250 mm, 5 mm) at
40 8C and eluting with isocratic 50:50 MeOH/CO2 with 0.2% v/v
NH3 at a flow rate of 4 mLmin
@1. The injection volume was 1.0 mL
and the peaks were detected at 210–400 nm. Chemical purity of
the enantiomers was analysed using an Acquity BEH C18 column
(50V2.1 mm, 1.7 mm) at 40 8C and eluting with 0–4 min gradient of
5–95% MeCN/H2O with 0.1% TFA, 4-4.02 min gradient of 95–100%
MeCN/H2O with 0.1% TFA, 4.03 min–4.5 min isocratic 100% MeCN
with 0.1% TFA, 4.5–4.52 min gradient of 100-5% MeCN/H2O with
0.1% TFA, and 4.53–6 min isocratic of 5% MeCN/H2O with 0.1%
TFA at flow rate 0.6 mLmin@1. The injection volume was 1.0 mL and
the peak was detected at 220 nm. The final yield is 82.7 mg of
enantiomer (S)-25 with 97.42% chemical purity and in 98.2% ee,
and 77.1 mg of enantiomer (R)-25 with 98.75% chemical purity
and in 99.6% ee.
Determination of compound binding affinities at wild-type
and Ala147Thr TSPO
Binding affinities were measured as per our published protocol.[21]
Briefly, an Ultra-Turrax homogeniser was used to prepare mem-
branes from HEK cells stably transfected with wild-type and A147T
TSPO. These cells were previously validated as an in vitro model of
LABs and HABs.[21] Membranes (20 mg per well, diluted in 50 mm
Tris·HCl, pH 7.4) were incubated with &Kd concentration of [3H]1
(10 nm ; PerkinElmer) and test compounds (0.3 nm–10 mm) at 4 8C
for 90 min. Reactions were terminated by filtration through a 96-
well glass-fibre filter plate (Millipore), and washed eight times with
ice-cold 50 mm Tris·HCl. Microscint 0 was added to the dry filters,
and radioactivity read in a Microbeta2 2450 Microplate Counter
(PerkinElmer). Data were analysed using GraphPad Prism 6.0, and a
four-parameter nonlinear regression curve fit was used to calculate
Ki values. Data are expressed as the mean:SEM from at least
three independent experiments.
ChemMedChem 2019, 14, 982 – 993 www.chemmedchem.org T 2019 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim991
Full Papers
Circular dichroism spectroscopy. Solutions of (S)-6, (R)-6, and (S)-5
were prepared in concentrations of 0.1–0.2 mgmL@1 in acetonitrile
and CD spectra were collected on an Aviv 410 instrument.
Radiochemistry
Radioisotope production. No-carrier-added aqueous [18F]fluoride
ion was produced on a GE PETtrace cyclotron by irradiation of a
2.3-mL silver-bodied water target with a 25-mA current and a 16.5-
MeV proton beam on 95% enriched 18O-H2O via the nuclear
18O(p,n)18F reaction.
Preparation of the [18F]KF-Kryptofix-222 complex. [18F]Fluoride in
[18O]H2O was transferred and immediately trapped on an anion-ex-
change resin (Waters Sep-Pak Accell Light QMA cartridge in the
carbonate form) under vacuum. Trapped 18F-fluoride was eluted
from the Sep-Pak cartridge and transferred to the reaction vessel
with an eluent solution containing 0.25% wild-type Kryptofix-222S
solution (1 mL) in basic (0.05% wild-type K2CO3) aq. MeCN (75% v/
v). The solvents were evaporated in vacuo (130 mbar) with a
stream of N2 gas at 95 8C over 5 min. Anhydrous MeCN (3V0.7 mL)
was then added and the mixture was azeotropically dried in vacuo
(130 mbar) with a stream of N2 at 95 8C.
Manual preparation of [18F]6. Fluoride was dried as described
above and dissolved in MeCN (4 mL) before eluting from TRACER-
lab FXFN. The resulting solution was divided into three portions,
two of which the MeCN was removed at 100 8C under a flow of N2
before dissolving in DMF or DMSO. Precursors 25 and 26 were dis-
solved to a concentration of 1 mgmL@1 in MeCN, DMSO and DMF
to afford three solutions of each precursor. For each reaction, four
HPLC vials were prepared containing precursor solution (125 mL)
and [18F]fluoride solution (125 mL) of equivalent solvent. The vials
were heated in a heating block to the desired temperature (80, 100
or 1208C) and a single vial was removed at each time point (2, 5,
10, 20 min) and quenched with 1:1 MeCN/H2O (300 mL) before ana-
lyzing directly by HPLC using a gradient method: (pre-injection)
1 min equilibration at 10:90 MeCN/H2O. (post-injection) 1 min iso-
cratic at 10:90 MeCN/H2O, 2 min gradient to 70:30 MeCN/H2O,
3 min isocratic at 70:30 MeCN/H2O. Flow rate: 1.5 mLmin
@1. Run
time: 6 min (7 min including equilibration time). Column: ACES Ul-
traCore, Super C18, 2.5 mm, 50V4.6 mm; Serial No. A133239. A por-
tion of the sample from 20 min was taken and used for co-injection
with reference compound 6 to confirm synthesis of desired product.
Automated preparation and formulation of [18F]6. The tosylate
precursor 25 (1.2 mg, 2.94 mmol) was dissolved in anhydrous MeCN
(1 mL), and the solution was added to the dry [18F]KF-Kryptofix-222
complex and heated at 100 8C for 20 min. The reaction mixture
was then cooled with compressed air and diluted with anhydrous
MeCN (1 mL). The crude mixture was injected into an ACE 160433
C18 5 mm (100V10 mm) semipreparative reversed-phase HPLC
column. With a mobile phase of 48% aq. MeCN at a flow rate of
5 mLmin@1. [18F]6 was collected (tR : 19.6 min) and immediately di-
luted with H2O (10 mL). The aqueous solution was passed through
a C18 cartridge (Waters Sep-Pak Accell Light C18 cartridge, prepared
by washing with 2 mL of ethanol, rinsing with 10 mL of water). The
cartridge was washed with H2O (15 mL) and the radiolabelled
product was eluted with EtOH (0.5 mL). The radiolabelled product
was then formulated with 0.9% w/v aq. NaCl in a vial to afford the
radiolabelled title compound.
Quality control for [18F]6. To confirm the identity of the formulat-
ed radiotracer, and for the determination of molar radioactivity
and radiochemical purity, a portion of the final solution with
known radioactivity was injected into a Phenomenex Luna 5 mm
C18 (2) 100 a (250V4.6 mm) analytical reversed-phase HPLC
column. A mobile phase of 0–3 min isocratic at 10% aq. MeCN, 3–
5 min gradient 10–80% aq. MeCN, and 6–12 min isocratic 80% aq.
MeCN at a flow rate of 1.5 mLmin@1 to elute [18F]6 at a tR of
9.8 min. The area of the UV absorbance peak at 220 nm corre-
sponding to the carrier product was measured (integrated) on the
HPLC chromatogram and compared with a standard curve relating
mass to UV absorbance. The identity of the radiolabelled product
was confirmed by HPLC co-injection of the reference compound 6.
In vivo PET imaging
Male Wistar rats (n=2; weight: 230 and 302 g) were obtained from
Charles River Laboratories, UK. The rats were housed in Techniplast
2000P IVC cages on a layer of Aspen bedding in a room with con-
stant temperature (21:2 8C) and fixed 12 h light–dark regime
(lights on at 7:00 am). Food and water were available ad libitum.
After arrival, the rats were allowed to acclimatise for at least seven
days. This research was regulated under the Animals (Scientific Pro-
cedures) Act 1986 Amendment Regulations 2012 following ethical
review by the University of Cambridge Animal Welfare and Ethical
Review Body (AWERB).
Prior to scanning, the animals were anaesthetised using isofluorane
at a concentration of 5% in O2, and anaesthesia was maintained at
1.5–2.5% isofluorane in O2. The femoral vein was cannulated for
tracer injection. Body temperature was maintained at 37 8C using
an electronic heating blanket. Anaesthetised rats were placed, one
per scanning session, in a microPET Focus 120 scanner (modified
in house according to the reference).[22] They were positioned on a
heating mat in transaxial position with their head in the field of
view. A transmission scan of 515 s with a 68Ge point source was
made for attenuation and scatter correction of 511 keV photons.
The radiotracer, formulated in saline, was injected to the rats and
the emission scan was started with tracer injection. A list-mode
protocol was used with an acquisition time of 60 min.
Image reconstructions were performed using microPET Manager
2.4.1.1, ASIPro 6.7.1.2 (Siemens). Acquisition data were then Fourier
re-binned in 22 time frames (6V10 s, 4V30 s, 4V60 s, 1V180 s, 4V
300 s, 3V600 s) and the data were reconstructed per timeframe
employing an iterative reconstruction algorithm (ordered subsets
expectation maximisation, OSEM 2D with Fourier re-binning, four
iterations, and 16 subsets). The final datasets consisted of 95 slices
with a slice thickness of 0.8 mm, and an in-plane image matrix of
128V128 pixels. Voxel size was 0.8V0.8V0.8 mm. Data sets were
corrected for decay, random coincidences, scatter and attenuation.
Three-dimensional regions of interest (ROIs) were drawn over the
whole brain on an MRI template using PMOD software (version
3.2; PMOD technologies, Zurich, Switzerland). PET images were
then co-registered with this MRI template and the regions of inter-
est transferred from MRI to PET. Whole-brain TACs were then ob-
tained for each of the animals. The results were expressed as di-
mensionless standardised uptake values (SUV= [(tissue activity)V
(body weight)]/injected dose). SUVs were calculated assuming a
specific gravity of 1 gmL@1 for brain tissue.
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